ePT--the Electronic Newsletter of Pharmaceutical Technology, Jul 19, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Jul 19, 2012
News
GSK to Acquire Human Genome Sciences for $3.6 Billion
By Stephanie Sutton
GlaxoSmithKline has announced that it will acquire Human Genome Sciences (HGS) for $14.25 per share in cash, or approximately $3.6 billion on an equity basis.
IMS Institute for Healthcare Informatics Issues Forecast for Global Medicine Use
By Jennifer Markarian
Global spending on medicines is estimated to reach nearly $1.2 trillion by 2016.
Par Pharmaceuticals to be Acquired by TPG for $1.9 Billion
By Amy Ritter
Par Pharmaceuticals, a maker of generic drugs, has entered into an agreement to be acquired by the private investment firm, TPG, for $1.9 billion.
Week of July 16, 2012: Bristol-Myers Squibb Begins Tender Offer to Acquire Amylin Pharmaceuticals; FDA Approves Gilead's Truvada for Reducing the Risk of Acquiring HIV; and More
Bristol-Myers Squibb Begins Tender Offer to Acquire Amylin Pharmaceuticals; FDA Approves Gilead's Truvada for Reducing the Risk of Acquiring HIV; and More.
Regulatory Roundup: Week of July 16, 2012
FDA promotes supply chain pilot program. EMA opens pharmacovigilance legistation up for public consultation. USP Calls for Somatropin Cell-Based Bioidentity Method.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here